nach oben

The European Journal of Health Economics

Erschienen in:

17.07.2019 | Original Paper

Economic impact of disease prevention in a morbidity-based financing system: does prevention pay off for a statutory health insurance fund in Germany?

verfasst von: Ines Weinhold, Christian Schindler, Nils Kossack, Benjamin Berndt, Dennis Häckl

Erschienen in: The European Journal of Health Economics | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Preventable chronic diseases account for the greatest burden in the German health system and statutory health insurance (SHI) funds play a crucial role in implementing and financing prevention strategies. On the contrary, the morbidity-based scheme to distribute financial resources from the Central Reallocation Pool among the different sickness funds may counteract efforts of effective prevention from an economic perspective. We assessed financial impacts of prevention from a sickness funds perspective in a retrospective controlled study. Claims data of 6,247,275 persons were analyzed and outcomes between two propensity-matched groups (n = 852,048) of prevention users and non-users were compared in a 4-year follow-up. Using a difference-in-differences approach, we analyzed healthcare expenditures, the development of morbidity, financial transfers from the Central Reallocation Pool, and contribution margins. The group of prevention users develops less morbidity (incidences and disease aggravations) compared to the control group. Healthcare expenditures increase in both groups within 4 years, whereas the increase is lower for prevention users compared to non-users (€568.04 vs. €640.60, p < 0.0001). Taking morbidity-based financial transfers into account, the decrease in contribution margins is stronger for prevention users (− €188.44 vs. − €138.73, p < 0.0001). This study demonstrates an economic disincentive from a sickness funds’ perspective. In the semi-competitive SHI market, sickness funds will be discouraged from effective prevention strategies if investments are not worth it financially. Their efforts and knowledge are, however, crucial for joint action to foster prevention over cure in the health system.

Nur mit Berechtigung zugänglich

Including strengthening of health competence and patient sovereignty, establishment of healthy environments that fit peoples’ living and working conditions, prevention of work-related health hazards, self-help promotion, vaccination, prevention of dental diseases, contraception, vasectomy, and abortion.

Including early diagnosis of cancer and preventive checkups for children and adolescents.

Insurance days per year are used for the weighting to devalue the econometric relevance of people with short insurance times.

Health policy recently increased the benchmark for SHI prevention investment per insurant. From 2016 sickness funds are required to invest 7 € per person in approaches to enhance healthy environments and working conditions and prevent work-related health risks (§ 20 Sect. (6) SGB V).

With a total market share of 8%.

i.e., compulsory member, dependent coverage (family insurance) or retired.

Since the Morbi-RSA is a prospective model, we received the financial transfers 2011–2015.

Assessed based on escalations in the Morbi-RSA hierarchies.

Bundesamt, Statistisches: Krankheitskosten 2002–2008. Fachserie 12, 36–41 (2010)

van der Meer, R.M., Wagena, E., Ostelo, R.W.J.G., Jacobs, A.J.E., van Schayck, O.C.P.: Smoking cessation for chronic obstructive pulmonary disease. In: van der Meer, R.M. (ed.) Cochrane Database of Systematic Reviews, p. CD002999. Wiley, Chichester (2003)

Wendel-Vos, G., Schuit, A.J., Feskens, E.J.M., Boshuizen, H.C., Verschuren, W.M.M., Saris, W.H.M., Kromhout, D.: Physical activity and stroke. A meta-analysis of observational data. Int. J. Epidemiol. 33, 787–798 (2004). https://doi.org/10.1093/ije/dyh168CrossRefPubMed

Ebrahim, S., Taylor, F., Ward, K., Beswick, A., Burke, M., Davey Smith, G.: Multiple risk factor interventions for primary prevention of coronary heart disease. In: Ebrahim, S. (ed.) Cochrane Database of Systematic Reviews. Wiley, Chichester (2011)

Rees, K., Dyakova, M., Wilson, N., Ward, K., Thorogood, M., Brunner, E.: Dietary advice for reducing cardiovascular risk. In: Brunner, E. (ed.) Cochrane Database of Systematic Reviews, p. CD002128. Wiley, Chichester (2013)

Busse, R., Blümel, M.: Health System Review. Health Systems in Transition. European Observatory on Health Systems and Policies. World Health Organization, Geneva (2014)

Die Bundesregierung: Präventionsstrategie, https://www.bundesregierung.de/Content/DE/_Anlagen/Nachhaltigkeit-wiederhergestellt/5-Berichte-Reden/2013-02-22-anlage-eckpunkte-der-praeventionsstrategie.pdf?__blob=publicationFile&v=2. Accessed 3 Aug 2016

Göpffarth, D.: Reforming Germany’s risk structure equalization scheme-taking stock at the halfway point. J. Public Health (Bangkok) 13, 248–256 (2005). https://doi.org/10.1007/s10389-005-0121-2CrossRef

van de Ven, W.P.M.M., Beck, K., Buchner, F., Chernichovsky, D., Gardiol, L., Holly, A., Lamers, L.M., Schokkaert, E., Shmueli, A., Spycher, S., Van de Voorde, C., van Vliet, R.C.J.A., Wasem, J., Zmora, I.: Risk Adjustment and risk selection on the sickness fund insurance market in five European countries. Health Policy (New York). 65, 75–89 (2003). https://doi.org/10.1016/s0168-8510(02)00118-5CrossRef

10.

Buchner, F., Göpffarth, D., Wasem, J.: The new risk adjustment formula in Germany: implementation and first experiences. Health Policy (New York). 109, 253–262 (2013). https://doi.org/10.1016/j.healthpol.2012.12.001CrossRef

11.

Busse, R., Drösler, S., Glaeske, G., Greiner, W., Schäfer, T., Schrappe, M.: Wissenschaftliches Gutachten für die Auswahl von 50 bis 80 Krankheiten zur Berücksichtigung im morbiditätsorientierten Risikostrukturausgleich (2007)

12.

WHO: Regional Office for the Eastern Mediterranean: Health promotion and disease prevention through population-based interventions, including action to address social determinants and health inequity, http://www.emro.who.int/about-who/public-health-functions/health-promotion-disease-prevention.html. Accessed 3 Aug 2016

13.

Katz, D.L., Ali, A.: Preventive medicine, integrative medicine, and the health of the public. Invited paper at the IOM Summit on Integrative Medicine and the Health of the Public., Washington, DC (2009)

14.

Deutsche Adipositas-Gesellschaft: Interdisziplinäre Leitlinien der Qualität S3 zur “Prävention und Therapie der Adipositas”. Martinsried (2014)

15.

Paulweber, B., Valensi, P., Lindström, J., Lalic, N., Greaves, C., McKee, M., Kissimova-Skarbek, K., Liatis, S., Cosson, E., Szendroedi, J., Sheppard, K., Charlesworth, K., Felton, A.-M., Hall, M., Rissanen, A., Tuomilehto, J., Schwarz, P., Roden, M., Paulweber, M., Stadlmayr, A., Kedenko, L., Katsilambros, N., Makrilakis, K., Kamenov, Z., Evans, P., Gilis-Januszewska, A., Lalic, K., Jotic, A., Djordevic, P., Dimitrijevic-Sreckovic, V., Hühmer, U., Kulzer, B., Puhl, S., Lee-Barkey, Y., AlKerwi, A., Abraham, C., Hardeman, W., Acosta, T., Adler, M., AlKerwi, A., Barengo, N., Barengo, R., Boavida, J., Charlesworth, K., Christov, V., Claussen, B., Cos, X., Cosson, E., Deceukelier, S., Dimitrijevic-Sreckovic, V., Djordjevic, P., Evans, P., Felton, A.-M., Fischer, M., Gabriel-Sanchez, R., Gilis-Januszewska, A., Goldfracht, M., Gomez, J., Greaves, C., Hall, M., Handke, U., Hauner, H., Herbst, J., Hermanns, N., Herrebrugh, L., Huber, C., Hühmer, U., Huttunen, J., Jotic, A., Kamenov, Z., Karadeniz, S., Katsilambros, N., Khalangot, M., Kissimova-Skarbek, K., Köhler, D., Kopp, V., Kronsbein, P., Kulzer, B., Kyne-Grzebalski, D., Lalic, K., Lalic, N., Landgraf, R., Lee-Barkey, Y., Liatis, S., Lindström, J., Makrilakis, K., McIntosh, C., McKee, M., Mesquita, A., Misina, D., Muylle, F., Neumann, A., Paiva, A., Pajunen, P., Paulweber, B., Peltonen, M., Perrenoud, L., Pfeiffer, A., Pölönen, A., Puhl, S., Raposo, F., Reinehr, T., Rissanen, A., Robinson, C., Roden, M., Rothe, U., Saaristo, T., Scholl, J., Schwarz, P., Sheppard, K., Spiers, S., Stemper, T., Stratmann, B., Szendroedi, J., Szybinski, Z., Tankova, T., Telle-Hjellset, V., Terry, G., Tolks, D., Toti, F., Tuomilehto, J., Undeutsch, A., Valadas, C., Valensi, P., Velickiene, D., Vermunt, P., Weiss, R., Wens, J., Yilmaz, T.: A European evidence-based guideline for the prevention of type 2 diabetes. Horm. Metab. Res. 42, S3–S36 (2010). https://doi.org/10.1055/s-0029-1240928CrossRefPubMed

16.

Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., An, Z.-X., Hu, Z.-X., Lin, J., Xiao, J.Z., Cao, H.-B., Liu, P.-A., Jiang, X.-G., Jiang, Y.-Y., Wang, J.-P., Zheng, H., Zhang, H., Bennett, P.H., Howard, B.: V: effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 20, 537–544 (1997)CrossRef

17.

Tuomilehto, J., Lindström, J., Eriksson, J.G., Valle, T.T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., Salminen, V., Aunola, S., Cepaitis, Z., Moltchanov, V., Hakumäki, M., Mannelin, M., Martikkala, V., Sundvall, J., Uusitupa, M.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344, 1343–1350 (2001). https://doi.org/10.1056/NEJM200105033441801CrossRefPubMed

18.

Gill, J.M.R., Cooper, A.R.: Physical activity and prevention of type 2 diabetes mellitus. Sport. Med. 38, 807–824 (2008)CrossRef

19.

Diabetes Prevention Program Reasearch: The10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention. Diabetes Care 35, 723–730 (2012). https://doi.org/10.2337/dc11-1468CrossRef

20.

Diabetes Prevention Program Research Group: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 3, 866–875 (2015). https://doi.org/10.1016/S2213-8587(15)00291-0CrossRefPubMedCentral

21.

Howard, B.V., Van Horn, L., Hsia, J., Manson, J.E., Stefanick, M.L., Wassertheil-Smoller, S., Kuller, L.H., LaCroix, A.Z., Langer, R.D., Lasser, N.L., Lewis, C.E., Limacher, M.C., Margolis, K.L., Mysiw, W.J., Ockene, J.K., Parker, L.M., Perri, M.G., Phillips, L., Prentice, R.L., Robbins, J., Rossouw, J.E., Sarto, G.E., Schatz, I.J., Snetselaar, L.G., Stevens, V.J., Tinker, L.F., Trevisan, M., Vitolins, M.Z., Anderson, G.L., Assaf, A.R., Bassford, T., Beresford, S.A.A., Black, H.R., Brunner, R.L., Brzyski, R.G., Caan, B., Chlebowski, R.T., Gass, M., Granek, I., Greenland, P., Hays, J., Heber, D., Heiss, G., Hendrix, S.L., Hubbell, F.A., Johnson, K.C., Kotchen, J.M.: Low-fat dietary pattern and risk of cardiovascular disease. JAMA 295, 655 (2006). https://doi.org/10.1001/jama.295.6.655CrossRefPubMed

22.

Hooper, L., Martin, N., Abdelhamid, A.: Davey Smith, G.: Reduction in saturated fat intake for cardiovascular disease. In: Hooper, L. (ed.) Cochrane Database of Systematic Reviews, p. CD011737. Wiley, Chichester (2015)

23.

Stevens, V.J., Obarzanek, E., Cook, N.R., Lee, I.M., Appel, L.J., Smith West, D., Milas, N.C., Mattfeldt-Beman, M., Belden, L., Bragg, C., Millstone, M., Raczynski, J., Brewer, A., Singh, B., Cohen, J.: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann. Intern. Med. 134, 1–11 (2001)CrossRef

24.

Löllgen, H.: Primärprävention kardialer Erkrankungen: Stellenwert der körperlichen Aktivität. Dtsch. Arztebl. 100, A987–A996 (2003)

25.

Sofi, F., Capalbo, A., Cesari, F., Abbate, R., Gensini, G.F.: Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur. J. Cardiovasc. Prev. Rehabil. 15, 247–257 (2008). https://doi.org/10.1097/HJR.0b013e3282f232acCrossRefPubMed

26.

Weinstein, A.R., Sesso, H.D., Lee, I.-M., Rexrode, K.M., Cook, N.R., Manson, J.E., Buring, J.E., Gaziano, J.M.: The joint effects of physical activity and body mass index on coronary heart disease risk in women. Arch. Intern. Med. 168, 884 (2008). https://doi.org/10.1001/archinte.168.8.884CrossRefPubMed

27.

Heran, B.S., Chen, J.M.H., Ebrahim, S., Moxham, T., Oldridge, N., Rees, K., Thompson, D.R., Taylor, R.S.: Exercise-based cardiac rehabilitation for coronary heart disease. In: Taylor, R.S. (ed.) Cochrane Database of Systematic Reviews, p. CD001800. Wiley, Chichester (2011)

28.

Jee, S.H., Suh, I., Kim, I.S., Appel, L.J.: Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study. JAMA 282, 2149–2155 (1999)CrossRef

29.

Wendel-Vos, G., Schuit, A., Feskens, E.: Physical activity and stroke. A meta-analysis of observational data. Int. J. 33, 787–798 (2004)

30.

Chiuve, S.E., Rexrode, K.M., Spiegelman, D., Logroscino, G., Manson, J.E., Rimm, E.B.: Primary prevention of stroke by healthy lifestyle. Circulation 118, 947–954 (2008). https://doi.org/10.1161/CIRCULATIONAHA.108.781062CrossRefPubMedPubMedCentral

31.

Andreas, S., Batra, A., Behr, J., Berck, H., Chenot, J.F., Gillissen, A., Hering, T., Herth, F., Meierjürgen, R., Mühlig, S., Nowak, D., Pfeifer, M., Raupach, T., Schultz, K., Sitter, H., Worth, H.: Tabakentwöhnung bei COPD: S3 leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie. 62, 255–272 (2008). https://doi.org/10.1055/s-2008-1038148CrossRefPubMed

32.

Goeckejan, G., Sitter, H., Thomas, M., Branscheid, D., Al, E.: Praevention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms—Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie. 64, e1–e164 (2010). https://doi.org/10.1055/s-0029-1243837CrossRef

33.

Neusser, S., Krauth, C., Hussein, R., Bitzer, E.M.: Clinical effectiveness and cost-effectiveness of fissure sealants in children and adolescents with a high caries risk. GMS Health Technol. Assess. 10, 1–9 (2014). https://doi.org/10.3205/hta000118CrossRef

34.

Taylor, F., Huffman, M.D., Macedo, A.F., Moore, T.H.M., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S.: Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. (2013). https://doi.org/10.1002/14651858.cd004816.pub5CrossRefPubMedPubMedCentral

35.

Hewitson, P., Glasziou, P., Watson, E., Towler, B., Irwig, L.: Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am. J. Gastroenterol. 103, 1541–1549 (2008). https://doi.org/10.1111/j.1572-0241.2008.01875.xCrossRefPubMed

36.

Atkin, W.S., Edwards, R., Kralj-Hans, I., Wooldrage, K., Hart, A.R., Northover, J.M., Parkin, D.M., Wardle, J., Duffy, S.W., Cuzick, J.: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375, 1624–1633 (2010). https://doi.org/10.1016/S0140-6736(10)60551-XCrossRefPubMed

37.

Nishihara, R., Wu, K., Lochhead, P., Morikawa, T., Liao, X., Qian, Z.R., Inamura, K., Kim, S.A., Kuchiba, A., Yamauchi, M., Imamura, Y., Willett, W.C., Rosner, B.A., Fuchs, C.S., Giovannucci, E., Ogino, S., Chan, A.T.: Long-term colorectal-cancer incidence and mortality after lower endoscopy. N. Engl. J. Med. 369, 1095–1105 (2013). https://doi.org/10.1056/NEJMoa1301969CrossRefPubMed

38.

Hüppe, D., Hartmann, H., Felten, G., Kemen, M., Tannapfel, A., Gillessen, A., Katalinic, A.: Effectiveness of screening colonoscopy in a community-based study. Z. Gastroenterol. 46, 193–200 (2008). https://doi.org/10.1055/s-2007-963539CrossRefPubMed

39.

Breitbart, E.W., Waldmann, A., Nolte, S., Capellaro, M., Greinert, R., Volkmer, B., Katalinic, A.: Systematic skin cancer screening in Northern Germany. J. Am. Acad. Dermatol. 66, 201–211 (2012). https://doi.org/10.1016/j.jaad.2010.11.016CrossRefPubMed

40.

Leitlinienprogramm Onkologie: S3-Leitlinie Prävention von Hautkrebs (2014). https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Hautkrebspraeventationsleitlinie_1.1/LL_PraeventionHK_OL_Langversion_1.1.pdf. Accessed 3 Aug 2016

41.

Otto, S.J., Fracheboud, J., Looman, C.W., Broeders, M.J., Boer, R., Hendriks, J.H., Verbeek, A.L., de Koning, H.J.: Initiation of population-base mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361, 1411–1417 (2003). https://doi.org/10.1016/S0140-6736(03)13132-7CrossRefPubMed

42.

Health Council of the Netherlands: Population screening for breast cancer: expectations and developments. Den Haag (2014). ISBN 978-94-6281-011-2. https://www.lrcb.nl/resources/uploads/2017/02/201401EPopulation_screening_for_breast_cancer_expectations_and_developments-1.pdf

43.

Nyström, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjöld, B., Rutqvist, L.E.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359, 909–919 (2002). https://doi.org/10.1016/S0140-6736(02)08020-0CrossRefPubMed

44.

Duffy, S.W., Tabár, L., Chen, H.-H., Holmqvist, M., Yen, M.-F., Abdsalah, S., Epstein, B., Frodis, E., Ljungberg, E., Hedborg-Melander, C., Sundbom, A., Tholin, M., Wiege, M., Åkerlund, A., Wu, H.-M., Tung, T.-S., Chiu, Y.-H., Chiu, C.-P., Huang, C.-C., Smith, R.A., Rosén, M., Stenbeck, M., Holmberg, L.: The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95, 458–469 (2002). https://doi.org/10.1002/cncr.10765CrossRefPubMed

45.

Gotzsche, P.C., Jorgensen, K.J.: Screening for breast cancer with mammography. Cochrane Database Syst. Rev. 6, CD001877 (2013). https://doi.org/10.1002/14651858.cd001877.pub5CrossRef

46.

World Health Organization: WHO position paper on mammography screening. WHO, Geneva (2014)

47.

Deutsche Krebshilfe, Deutsche Krebsgesellschaft: Ihr Krebsrisiko—Sind sie gefährdet., Bonn (2015)

48.

Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., Denis, L.J., Recker, F., Paez, A., Bangma, C.H., Carlsson, S., Puliti, D., Villers, A., Rebillard, X., Hakama, M., Stenman, U.H., Kujala, P., Taari, K., Aus, G., Huber, A., Van Der Kwast, T.H., Van Schaik, R.H.N., De Koning, H.J., Moss, S.M., Auvinen, A.: Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027–2035 (2014). https://doi.org/10.1016/s0140-6736(14)60525-0CrossRefPubMedPubMedCentral

49.

GKV-Spitzenverband: Kennzahlen der gesetzlichen Krankenversicherung., Berlin (2016). https://www.gkv-spitzenverband.de/media/grafiken/gkv_kennzahlen/kennzahlen_gkv_2016_q1/GKV_Kennzahlen_Booklet_Q1-2016_300dpi_2016-06-30.pdf. Accessed 9 Aug 2016

50.

Bundesversicherungsamt: Festlegung der zu berücksichtigenden Krankheiten für das Ausgleichsjahr 2014 nach § 31 Abs. 4 Satz 1 RSAV., Bonn (2013). http://www.bundesversicherungsamt.de/fileadmin/redaktion/Risikostrukturausgleich/Festlegungen/AJ_2014/Festlegung_Krankheitsauswahl_2014.zip. Accessed 9 Aug 2016

51.

Bundesversicherungsamt: So funktioniert der neue Risikostrukturausgleich im Gesundheitsfonds., Bonn (2008). https://www.bundesversicherungsamt.de/fileadmin/redaktion/Risikostrukturausgleich/Wie_funktioniert_Morbi_RSA.pdf. Accessed 27 July 2016

52.

Bödeker, W.: Morbi-RSA und Prävention: Passt das zusammen? Die BKK 12, 634–641 (2010)

53.

Bödeker, W., Moebus, S.: Normen- und Anreizkonflikte für die gesetzlichen Krankenkassen in Gesundheitsförderung und Prävention. Das Gesundheitswes. 77, 397–404 (2015). https://doi.org/10.1055/s-0034-1384562CrossRef

54.

Monopolkommission: Stand und Perspektiven des Wettbewerbs im deutschen Krankenversicherungssystem., Bonn (2017). https://www.monopolkommission.de/images/PDF/SG/s75_volltext.pdf. Accessed 11 May 2018

55.

Bundesversicherungsamt: Festlegung der im morbiditätsorientierten Risikostrukturausgleich zu berücksichtigenden Krankheiten durch das Bundesversicherungsamt., Bonn (2008)

56.

Stock, S., Schmidt, H., Büscher, G., Gerber, A., Drabik, A., Graf, C., Lüngen, M., Stollenwerk, B.B., Forde, I., Raine, R., Szecsenyi, J., Rosemann, T., Joos, S., Peters-Klimm, F., Miksch, A., Schmidt, H., Wörz, M., Busse, R., Stock, S., Stollenwerk, B.B., Klever-Deichert, G., Redaelli, M., Büscher, G., Graf, C., Al, E., Schmidt, H., Blöß, T., Bödeker, W., Friedel, H., Friedrichs, M., Dreier, M., Linger, H., Schmidt, H., Bäscher, G., Gerber, A., Drabik, A., Graf, C., Längen, M., Stollenwerk, B.B.: Financial incentives in the German Statutory Health Insurance: new findings, new questions. Health Policy (New York). 96, 51–56 (2010). https://doi.org/10.1016/j.healthpol.2009.12.015CrossRef

57.

Bundesversicherungsamt: Festlegungen zur Krankheitsauswahl 2017., Bonn (2016). http://www.bundesversicherungsamt.de/fileadmin/redaktion/Risikostrukturausgleich/Festlegungen/AJ_2017/20160229_Festlegung_Krankheiten_AJ2017.zip. Accessed 29 Mar 2017

58.

Drösler, S., Garbe, E., Hasford, J., Schubert, I., Ulrich, V., van de Ven, W.P.M.M., Wambach, A., Wasem, J., Wille, E.: Sondergutachten zu den Wirkungen des morbiditätsorientierten Risikostrukturausgleichs., Bonn (2017). https://www.bundesversicherungsamt.de/fileadmin/redaktion/Risikostrukturausgleich/20180125Sondergutachten_Wirkung_RSA_2017_korr.pdf. Accessed 11 May 2018

59.

Drösler, S., Hasford, J., Kurth, B.-M., Schaefer, M., Wasem, J., Wille, E.: Evaluationsbericht zum Jahresausgleich 2009 im Risikostrukturausgleich (2011). https://www.bundesversicherungsamt.de/fileadmin/redaktion/Risikostrukturausgleich/Wissenschaftlicher_Beirat/Evaluationsbericht_zum_Jahresausgleich.pdf. Accessed 2 Aug 2016

60.

Abadie, A.: Semiparametric difference-in-differences estimators. Rev. Econ. Stud. 72, 1–19 (2005). https://doi.org/10.1111/0034-6527.00321CrossRef

61.

Austin, P.C.: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083–3107 (2009). https://doi.org/10.1002/sim.3697CrossRefPubMedPubMedCentral

62.

Cohen, J.: Statistical Power Analysis for the Behavioral Sciences. Lawrence Erlbaum Associates Inc., Hillsdale (1988)

63.

Stock, S., Stollenwerk, B., Klever-Deichert, G., Redaelli, M., Büscher, G., Graf, C., Möhlendick, K., Mai, J., Gerber, A., Lüngen, M., Lauterbach, K.W.: Preliminary analysis of short term financial implications of a prevention bonus program: first results from the German statutory health insurance. Int. J. Public Health. 53, 78–86 (2008). https://doi.org/10.1007/s00038-008-7026-0CrossRefPubMed

64.

Augurzky, B., Reichert, A., Schmidt, C.: The effect of a bonus program for preventive health behavior on health expenditures. Ruhr Econ. Pap. 373, 1–36 (2012). https://doi.org/10.4419/8678842CrossRef

65.

Bödeker, W., Friedrichs, M., Friedel, H.: Ökonomischer Nutzen von Bonusprogrammen für die Inanspruchnahme von Früherkennungs- und Präventionsmaßnahmen. Gesundheitswesen. 70, A38 (2008). https://doi.org/10.1055/s-0028-1086263CrossRef

66.

Plate, F., Demme, S.: Reformoptionen zum Risikostrukturausgleich - Kühler Kopf und klarer Blick gefragt! Welt der Krankenversicherung. 7–8, 172–175 (2016)

67.

Welch, H.G., Black, W.C.: Overdiagnosis in cancer. J. Natl Cancer Inst. 102, 605–613 (2010). https://doi.org/10.1093/jnci/djq099CrossRefPubMed

68.

Schöffski, O., von der Graf Schulenburg, J.-M. (eds.): Gesundheitsökonomische Evaluationen. Springer, Berlin (2012)

69.

Bundesministerium für Gesundheit: Entwurf eines Gesetzes für eine faire Kassenwahl in der gesetzlichen Krankenversicherung, https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/Downloads/Gesetze_und_Verordnungen/GuV/G/RefE_Gesetz_fuer_eine_faire_Kassenwahl_in_der_GKV.pdf. Accessed 7 May 2019

Titel: Economic impact of disease prevention in a morbidity-based financing system: does prevention pay off for a statutory health insurance fund in Germany?
verfasst von: Ines Weinhold
Christian Schindler
Nils Kossack
Benjamin Berndt
Dennis Häckl
Publikationsdatum: 17.07.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: The European Journal of Health Economics / Ausgabe 8/2019
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-019-01086-7

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Investigating medical malpractice victim compensation: micro-level evidence from a professional liability insurer’s files

Developing the role of electronic health records in economic evaluation

International impact of external reference pricing: should national policy-makers care?

The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review

Mapping the kidney disease quality of life 36-item short form survey (KDQOL-36) to the EQ-5D-3L and the EQ-5D-5L in patients undergoing dialysis

Sustainability of public finances: inclusion of unrelated medical cost only part of the story